Latest Psoriasis Stories
One human antibody known as BI 655066 is a promising candidate to be used to target the inflammation-causing protein, interleukin-23.
DALLAS, March 13, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Hidradenitis Suppurativa - Pipeline Review, H1 2015" therapeutic market research report provides an overview
Beverly Hills’ celebrity cosmetic dermatologist and renowned expert on advanced skin treatments, Dr. Paul W.
AUSTIN, Texas, March 4, 2015 /PRNewswire/ -- XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA
COSENTYX(TM) (secukinumab), recently FDA-approved to treat plaque psoriasis, will be available for patients through the nation's largest independent specialty pharmacy. FLINT,
Dermatology offices, psoriasis patients encouraged to join the research efforts PORTLAND, Ore., Feb.
Celgene Launches Psoriatic Arthritis Educational Patient-Focused Program SUMMIT, N.J., Feb.
Southern Indiana Dermatologists Expand to Reach Patients In Central Indiana Greenwood, Indiana (PRWEB) February 17, 2015 Continuing to address the skin
PORTLAND, Ore., Feb.
Company just completed Phase II/III psoriasis trial and expects to release top line data in Q1 2015 PETACH TIKVA, Israel, Feb.
- An armed gangster.